Alaunos Therapeutics
TCRTTCRT · Stock Price
Historical price data
Overview
Alaunos Therapeutics is executing a dual-platform strategy to develop novel therapies for obesity and cancer. Its lead program is an oral, small molecule for obesity that deliberately avoids the incretin hormone pathway, aiming for improved tolerability and a differentiated metabolic profile, with proof-of-concept established in preclinical models. Concurrently, the company's hunTR® platform enables rapid discovery and validation of T-cell receptors for engineered cell therapies. As a micro-cap, pre-revenue public company, Alaunos represents a high-risk, high-potential investment focused on advancing these platforms toward clinical validation.
Technology Platform
Dual-platform: 1) An oral, non-incretin small molecule discovery platform for obesity; 2) The hunTR® high-throughput T-cell receptor (TCR) discovery and validation platform for cell therapy.
Pipeline
39| Drug | Indication | Stage | Watch |
|---|---|---|---|
| doxorubicin in combination with palifosfamide-tris + doxorub... | Soft Tissue Sarcoma | Phase 3 | |
| Carboplatin + Palifosfamide-tris + Etoposide + Carboplatin | Extensive-Stage Small Cell Lung Cancer | Phase 3 | |
| Palifosfamide Tris and Doxorubicin + Doxorubicin | Soft Tissue Sarcoma | Phase 2 | |
| Ad-RTS-hIL-12 + Veledimex + Cemiplimab-Rwlc | Glioblastoma | Phase 2 | |
| palifosfamide | Adult Central Nervous System Germ Cell Tumor | Phase 2 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
In obesity, Alaunos competes against dominant GLP-1/GIP-based therapies from Novo Nordisk and Eli Lilly, as well as other novel oral approaches. Its differentiation is its non-incretin, oral strategy. Its TCR platform competes with other TCR discovery and cell therapy engineering companies, positioning it as a potential technology partner.